Cargando…
Classification of clear cell renal cell carcinoma based on PKM alternative splicing
Clear cell renal cell carcinoma (ccRCC) accounts for 70–80% of kidney cancer diagnoses and displays high molecular and histologic heterogeneity. Hence, it is necessary to reveal the underlying molecular mechanisms involved in progression of ccRCC to better stratify the patients and design effective...
Autores principales: | Li, Xiangyu, Turanli, Beste, Juszczak, Kajetan, Kim, Woonghee, Arif, Muhammad, Sato, Yusuke, Ogawa, Seishi, Turkez, Hasan, Nielsen, Jens, Boren, Jan, Uhlen, Mathias, Zhang, Cheng, Mardinoglu, Adil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033363/ https://www.ncbi.nlm.nih.gov/pubmed/32095654 http://dx.doi.org/10.1016/j.heliyon.2020.e03440 |
Ejemplares similares
-
Stratification of patients with clear cell renal cell carcinoma to facilitate drug repositioning
por: Li, Xiangyu, et al.
Publicado: (2021) -
Discovery of Functional Alternatively Spliced PKM Transcripts in Human Cancers
por: Li, Xiangyu, et al.
Publicado: (2021) -
Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach
por: Li, Xiangyu, et al.
Publicado: (2022) -
Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning
por: Turanli, Beste, et al.
Publicado: (2019) -
Drug Repositioning for Effective Prostate Cancer Treatment
por: Turanli, Beste, et al.
Publicado: (2018)